Penumbra’s thrombectomy business leads 16% quarterly sales growth

Penumbra ($PEN) reported third-quarter 2026 revenue of $410.1 million, up 15.6%, as demand for its clot-removal systems expanded. Thrombectomy sales increased 18.1% to $279.2 million, including 26% growth in the US venous-thromboembolism business. Revenue from embolization and access products rose 10.8% to $131.0 million, providing growth across both operating categories.

Gross margin improved by half a percentage point to 68.3%. Operating income reached $50.7 million and net income was $42.3 million, although operating expenses included $7.1 million of acquisition-related costs. Penumbra’s agreed sale to Boston Scientific ($BSX) remains pending, and the company did not issue a 2026 financial outlook or hold an earnings call. The results describe Penumbra’s standalone operating performance; they do not establish that the acquisition has received all approvals or closed.

Sources:

• PR Newswire